Spago Nanomedical Q3 2022: Tumorad closing in on clinical development - Redeye

Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrapping up its phase I SAGOPIX-01 trial with contrast agent SpagoPix (SN132D) and initiating a phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). We review our estimates and make some adjustments to our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/861860/spago-nanomedical-q3-2022-tumorad-closing-in-on-clinical-development?utm_source=finwire&utm_medium=RSS